Columbus Circle Investors increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 9.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,532,911 shares of the biopharmaceutical company’s stock after acquiring an additional 136,515 shares during the quarter. Columbus Circle Investors owned approximately 2.23% of TG Therapeutics worth $18,165,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in TGTX. Legal & General Group Plc boosted its position in TG Therapeutics by 4.1% during the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 384 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in TG Therapeutics during the second quarter worth approximately $156,000. Bank of America Corp DE boosted its position in TG Therapeutics by 11.0% during the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 1,395 shares during the last quarter. HighTower Advisors LLC acquired a new stake in TG Therapeutics during the first quarter worth approximately $170,000. Finally, BB&T Securities LLC boosted its position in TG Therapeutics by 63.0% during the second quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock worth $170,000 after acquiring an additional 6,549 shares during the last quarter. Hedge funds and other institutional investors own 49.58% of the company’s stock.
Shares of TG Therapeutics, Inc. (NASDAQ TGTX) traded down $0.60 during mid-day trading on Friday, hitting $7.70. 1,554,552 shares of the stock were exchanged, compared to its average volume of 1,309,055. TG Therapeutics, Inc. has a fifty-two week low of $4.10 and a fifty-two week high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. sell-side analysts forecast that TG Therapeutics, Inc. will post -1.86 earnings per share for the current year.
A number of equities analysts have weighed in on TGTX shares. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target (up previously from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Zacks Investment Research downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, ValuEngine downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $26.78.
TRADEMARK VIOLATION NOTICE: “Columbus Circle Investors Has $18.17 Million Position in TG Therapeutics, Inc. (TGTX)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/19/columbus-circle-investors-has-18-17-million-position-in-tg-therapeutics-inc-tgtx.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.